ReviewJournal of internal medicine2014
Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.
Review in Journal of internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.Advances in therapy · 2024Pooled it
- Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).BMJ open · 2017 · on this mapTrial
- Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.Journal of diabetes research · 2016Trial
- Efficacy and Risks of Dextrose Infusion to Prevent Postoperative Nausea: a Narrative Review.Advances in therapy · 2026Review
- SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.International journal of molecular sciences · 2024Review
- Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report.Medicina (Kaunas, Lithuania) · 2023Article
- Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options.Molecules (Basel, Switzerland) · 2023Review
- Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases.Reviews in cardiovascular medicine · 2023Review
- Disparities in efficacy and safety of sodium-glucose cotransporter 2 inhibitor among patients with different extents of renal dysfunction: A systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2022Article
- Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.European journal of clinical pharmacology · 2021Review
- Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with AMolecules (Basel, Switzerland) · 2021Article
- The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium-glucose cotransporter 2) inhibitors.European heart journal supplements : journal of the European Society of Cardiology · 2020Article
- SGLT2 inhibition to address the unmet needs in diabetic nephropathy.Diabetes/metabolism research and reviews · 2019Review
- Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice.Diabetes & metabolism journal · 2019Article
- 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus.Clinical pharmacology : advances and applications · 2018Article
- The NLPR3 inflammasome and obesity-related kidney disease.Journal of cellular and molecular medicine · 2018Review
- SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.International journal of molecular sciences · 2017Review
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.Diabetologia · 2017Review
- Molecular cloning of glucose transporter 1 in grouper Epinephelus coioides and effects of an acute hyperglycemia stress on its expression and glucose tolerance.Fish physiology and biochemistry · 2017Article
- The Metabolic Syndrome and Its Components in African-American Women: Emerging Trends and Implications.Frontiers in endocrinology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Maintaining normoglycaemia not only reduces the risk of diabetic microvascular complications but also corrects the metabolic abnormalities that contribute to the development and progression of hyperglycaemia, that is insulin resistance and beta-cell dysfunction. Progressive beta-cell failure, in addition to side effects associated with many current antidiabetic agents, for example hypoglycaemia and weight gain, presents major obstacles to the achievement of the recommended goal of glycaemic control in patients with type 2 diabetes mellitus (T2DM). Thus, novel effective therapies are needed for optimal glucose control in subjects with T2DM. Most recently, specific inhibitors of the renal sodium-glucose cotransporter 2 (SGLT2) have been developed to produce glucosuria and lower the plasma glucose concentration. Because of the iR unique mechanism of action, which is independent of insulin secretion and insulin action, these agents are effective in lowering the plasma glucose concentration in all stages of the disease and can be combined with all other antidiabetic agents. In this review, we will summarize the available data concerning the mechanism of action, efficacy and safety of this novel class of antidiabetic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.